Table 2 Univariate and multivariate associations of CD44/CD24 expression and other risk factors with gastric cancer recurrence
From: CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Characteristics | Recurrence rate | Univariate | P -value | Model 1† | P -value | Model 2‡ | P -value |
|---|---|---|---|---|---|---|---|
OR (95%CI) | aOR (95%CI) | aOR (95%CI) | |||||
CD44 expression | |||||||
CD44- | 50.0% (10/20) | 1.00 (reference) | -- | 1.00 (reference) | -- | ||
CD44+ | 50.0% (10/20) | 1.00 (0.29-3.45) | 1.000 | 0.66 (0.10-4.26) | 0.658 | ||
CD24 expression | |||||||
CD24- | 43.5% (10/23) | 1.00 (reference) | -- | 1.00 (reference) | -- | ||
CD24+ | 58.8% (10/17) | 1.86 (0.52-6.61) | 0.339 | 0.09 (0.01-1.35) | 0.081 | ||
CD44 / CD24 expression | |||||||
CD44-/CD24- | 38.5% (5/13) | 1.00 (reference) | -- | 1.00 (reference) | -- | ||
CD44-/CD24+ | 71.4% (5/7) | 4.00 (0.55-29.10) | 0.171 | 0.60 (0.03-10.67) | 0.731 | ||
CD44+/CD24- | 50.0% (5/10) | 1.60 (0.30-8.49) | 0.581 | 1.61 (0.15-17.36) | 0.695 | ||
CD44+/CD24+ | 50.0% (5/10) | 1.60 (0.30-8.49) | 0.581 | 0.06 (0.002-2.31) | 0.131 | ||
Gender | |||||||
Male | 63.2% (12/19) | 2.79 (0.77-10.04) | 0.117 | 39.64 (1.85-848.44) | 0.019* | 21.59 (1.24-377.26) | 0.035* |
Female | 38.1% (8/21) | 1.00 (reference) | -- | 1.00 (reference) | -- | 1.00 (reference) | -- |
Age (years) | |||||||
≤65 | 37.5% (6/16) | 1.00 (reference) | -- | 1.00 (reference) | -- | 1.00 (reference) | -- |
>65 | 58.3% (14/24) | 2.33 (0.64-8.54) | 0.201 | 7.77 (0.89-67.99) | 0.064 | 4.07 (0.49-34.16) | 0.196 |
Histology | |||||||
Moderately differentiated (intestinal type) | 60.0% (9/15) | 1.91 (0.52-7.01) | 0.330 | ||||
Poorly differentiated (diffuse type) | 44.0% (11/25) | 1.00 (reference) | -- | ||||
Tumor location | |||||||
Upper third + Middle third | 37.5% (6/16) | 1.00 (reference) | -- | ||||
Lower third | 58.3% (14/24) | 2.33 (0.64-8.54) | 0.201 | ||||
TNM Stage | |||||||
I-IIa | 21.1% (4/19) | 1.00 (reference) | -- | 1.00 (reference) | -- | 1.00 (reference) | -- |
III-IV | 76.2% (16/21) | 12.0 (2.70-53.3) | 0.001* | 9.63 (1.05-88.76) | 0.046* | 41.01 (3.62-464.91) | 0.003* |
Lymph node metastasis | |||||||
No | 15.4% (2/13) | 1.00 (reference) | -- | 1.00 (reference) | -- | ||
Yes | 66.7% (18/27) | 11.0 (2.00-60.5) | 0.006* | 20.92 (1.20-365.55) | 0.037* | ||
Number of lymph node metastasis | |||||||
0 | 15.4% (2/13) | 1.00 (reference) | -- | ||||
1-4 s | 60.0% (9/15) | 8.25 (1.33-51.2) | 0.024* | ||||
≥5 | 75.0% (9/12) | 16.5 (2.25-121.2) | 0.006* |